Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Launched by ISTITUTO ORTOPEDICO RIZZOLI · Jan 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying Ewing sarcoma, a type of bone cancer, to understand what factors may affect how well patients do after treatment. Researchers want to see if things like age, sex, the size and location of the tumor, how much the tumor shrinks after chemotherapy, and certain biological markers can help predict overall survival and how likely a patient is to remain cancer-free after treatment. By finding reliable indicators of higher risk, doctors can better tailor treatments and follow-up care for these patients.

To participate in this trial, patients must be between the ages of 2 and 730 and have been diagnosed with Ewing sarcoma. They also need to have been treated at the Rizzoli Orthopaedic Institute from January 1991 to December 2021, and their clinical and imaging data should be available for review. Those who meet these criteria will contribute to important research that could improve understanding and treatment of Ewing sarcoma. Participants can expect to provide information about their medical history and possibly undergo some tests, all of which aim to help improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021
• • Age ≥ 2 years
• • Diagnosis of Ewing Sarcoma
• • Patients with available clinical and imaging data
• Exclusion Criteria:
• • At least one inclusion criterion not met